Stephen L. Hurst - Jan 1, 2022 Form 3 Insider Report for Mind Medicine (MindMed) Inc. (MNMD)

Role
Director
Signature
/s/ Robert Barrow, Attorney-in-Fact
Stock symbol
MNMD
Transactions as of
Jan 1, 2022
Transactions value $
$0
Form type
3
Date filed
1/10/2022, 08:31 PM
Next filing
Mar 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MNMD Subordinate Voting Shares 100 Jan 1, 2022 Direct
holding MNMD Subordinate Voting Shares 39M Jan 1, 2022 By Savant Addiction Medicine, LLC F1
holding MNMD Subordinate Voting Shares 1.72M Jan 1, 2022 By Sunray Asset Management F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MNMD Stock Option (Right to Buy) Jan 1, 2022 Subordinate Voting Shares 26.3K $2.91 Direct F3, F4
holding MNMD Directors' Deferred Share Units Jan 1, 2022 Subordinate Voting Shares 22.4K Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are owned by Savant Addiction Medicine, LLC ("Savant Addiction"). The Reporting Person is the managing member of Savant Addiction. The Reporting Person disclaims beneficial ownership of the shares owned by Savant Addiction except to the extent of his pecuniary interest therein.
F2 These shares are owned by Sunray Asset Management, Inc. ("Sunray"). The Reporting Person is the Managing Director of Sunray. The Reporting Person disclaims beneficial ownership of the shares owned by Sunray except to the extent of his pecuniary interest therein.
F3 The shares underlying the option shall vest and become exercisable in 12 equal monthly installments beginning on March 15, 2021, subject to the Reporting Person providing continuous service to the Issuer on each such date.
F4 The option grant has an exercise price of $3.70 Canadian Dollars. This represents the exercise price in United States Dollars.
F5 Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 12 months beginning on March 27, 2021. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan).

Remarks:

Exhibit List - Exhibit 24- Power of Attorney